Bill Caple serves as the Chairman of Oligomerix. Mr. Caple is a corporate strategist, management consultant, technology company serial founder/executive, and international investment banker and advisor. He has served in top executive and board positions with enterprise software organizations, biotech companies, and other growth companies, both private and public. Mr. Caple focuses on devising and implementing corporate finance strategies and business acceleration programs, netting successful exits and public offerings of his companies (e.g. OTG Software NASDAQ: OTGS). In addition to Oligomerix, Mr. Caple presently serves on the board of directors of Splash Beverage (NYSE American: SBEV) to assist with corporate strategies, business development, M&A, and growth. Mr. Caple also founded and runs Caple Advisory, an international management consulting practice and investment banking firm, with a concentration in Asia. In 2021, Caple Advisory lead, negotiated, and closed the notable $1.8B acquisition of TaylorMade Golf by the Korean private equity firm, Centroid Investment Partners. Mr. Caple has also managed numerous other successful corporate financings with leading VC firms and PE groups, and began his career as a corporate securities attorney with a top 10 national law firm.
Dr. Moe has 30 years industrial experience having held senior management positions in product development working on international teams in both early and late stage diagnostic, biotechnology and biopharmaceutical companies including Gene-Trak/Amoco Technology Ventures/Vysis, bioMerieux, and Mosaic Technologies. Prior to founding Oligomerix, he was Director of Product Development at Pyrosequencing, Senior Molecular Biologist at Spire Biomedical, and Director of Product Development at Q-RNA, Inc. Dr. Moe received his Ph.D. degree in Molecular Biology/Molecular Biophysics from Wesleyan University, did his postdoctoral studies at Vanderbilt University in the Center for Molecular Toxicology where he was jointly appointed in the Biochemistry Department in the Medical School, and the Chemistry Department in the College of Arts and Sciences, and has an MBA degree with a concentration in entrepreneurial studies from Boston University.
Dr. Davidowitz has over 20 years of professional experience in academic and industrial research and development. Prior to founding Oligomerix, he was a Senior Scientist at Q-RNA, Inc. Dr. Davidowitz received his B.S. from Cornell University, Ph.D. from Case Western Reserve University and completed an NIH postdoctoral fellowship at Albert Einstein College of Medicine. His academic work was in molecular and cellular biology and his industrial experience has focused on assay development for drug discovery targeting tau protein for Alzheimer’s disease.
Dr. Erhardt recently joined Oligomerix as Chief Medical Officer and will be responsible for transitioning Oligomerix’s lead compound through IND and into clinical development. Dr. Erhardt is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development. His background is complemented by significant organizational design and leadership experience. Prior to joining the company, he served as Senior Vice President, Head of Clinical Development & Operations at Pfizer responsible for design, conduct and reporting of Pfizer’s global Clinical Development portfolio. In this role, Dr. Erhardt was responsible for delivery for a portfolio of approximately 350 clinical studies across the Cardiovascular, Metabolic, Neuroscience, Vaccines, Immunology & Inflammation and Rare Disease therapeutic areas. Dr. Erhardt also spent several years at FDA as Medical Reviewer in the Division of Anti-Infective Drug Products and has excellent understanding of FDA processes. Dr. Erhardt has an ongoing role as a Senior Clinical Advisor supporting Operation Warp Speed and other aspects of the United States Government’s COVID19 response. Dr. Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse. He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children’s National Medical Center.
Mr. Pasini is the former Pfizer Vice President Worldwide Marketing, Product Development and Business Intelligence and Planning. Prior to joining Oligomerix, Mr. Pasini spent 30 years at Pfizer, Inc. where he held multiple senior level positions and was responsible for some of the company’s most successful brands including Spiriva, Zithromax, Diflucan and Zyvox. Among his career highlights, Mr. Pasini served as Vice President of Pfizer’s Infectious Diseases, Allergy & Respiratory Therapeutic Groups, where he led commercial decision-making involving two key therapeutic areas, generating annual revenue in excess of $5 billion.
Mr. Foerster joined Oligomerix in 2018 and took on responsibilities as CFO. In July 2022, Bob was promoted to take on the additional role of Chief Operating Officer. He is a seasoned pharmaceutical executive with experience across numerous financial, therapeutic and functional areas during his 28 years with Pfizer. His roles included Senior Director Commercial Development for Emerging Markets, Senior Director Business Development – Japan, where he was responsible for the entire development portfolio, numerous business alliances, strategic planning, and was a member of the Leadership team. He was Director/Team Leader – Neuroscience for New Product Development, which included the development of Chantix, and Director of Financial Operations for the Africa Middle East region where he was responsible for financial analysis, reporting and compliance. He received his BA in Economics from Dartmouth and MBA Finance from Rutgers.
Dr. Dantzker was a general partner with Wheatley MedTech Partners L.P. and manages Wheatley Partner’s Life Science and Healthcare investments. He was President of North Shore-LIJ Health System and co-founded the North Shore-LIJ Research Institute. He was Chair of the American Board of Internal Medicine and served senior appointments on the faculty at four medical schools. He is a member of the boards of five private and public companies and has served on numerous others in the past. Dr. Dantzker holds a B.A. in biology from NYU and received his M.D. from SUNY Buffalo School of Medicine.
Mr. Durand is the founder and managing director of Durand Venture Associates, LLC. Has 26 years of successful management, pharmaceutical sales and marketing experience. Former VP of sales, ePocrates Inc, executive director of marketing at AstraZeneca/Astra Pharmaceuticals, VP of sales, TAP Pharmaceuticals, and Director of Marketing and Regional Sales Director at Merck. He is a registered pharmacist, and a graduate of the University of Rhode Island.
Mr. Bluestein serves as Senior Managing Director of R.H. Bluestein & Co., an independent Registered Investment Advisor with offices in Birmingham, Michigan and New York City. Jeff’s role at the company is to aid in the management of assets of high-net-worth individuals and private institutions. The firm manages assets using a mix of traditional equities and fixed income securities as well as private equity opportunities. Jeff graduated from Cornell University with a Bachelor of Science and from the Ross School of Business at the University of Michigan with a Master’s in Business Administration. Prior to joining the firm, Jeff has been employed by Newman Financial Services, a boutique investment bank as well as Goldman, Sachs & Co.
Dr. Cassino is a physician/scientist whose career has spanned clinical medicine, pharmaceutical R&D and senior leadership in biotech. She has led the clinical development of wide range of new drugs to address unmet medical needs in respiratory, infectious disease, GI, cardiovascular and neuroscience. As Founder and President of Stony Point Life Sciences, Dr Cassino serves as a Senior Consultant to government agencies, corporate stakeholders and start ups. Dr. Cassino previously served as Chief Medical Officer and Executive Vice President of R&D at ContraFect Corporation, a publicly traded biotechnology company. Prior to this, she was Senior VP of Global Clinical Development at Forest Laboratories (now Abbvie), held several VP level R&D positions while at Pfizer and served as Executive Director of respiratory clinical development at Boehringer Ingelheim/US. Earlier in her career, Dr Cassino was an Assistant Professor of Medicine in the Division of Pulmonary/Critical Care Medicine at New York University (NYU) School of Medicine. She holds a B.A. in Chemistry and an M.D. from NYU and completed an Internal Medicine residency and a fellowship in Pulmonary Medicine at Bellevue Hospital/New York University Medical Center.
